Bruce Goodwin’s career with the Johnson & Johnson family of companies spans thirty five years.
He has been in General Management roles for the last ten years including two terms in his current role of Managing Director Janssen Australia and New Zealand, and also three years as President and Representative Director Janssen Japan.
Prior to General Management he has held Management Board Director positions in Sales and Marketing and in Finance, as well as having gained valuable experience in Global Licensing and Acquisitions. His service with Johnson & Johnson outside of his home country, Australia, includes postings to Janssen Japan, Janssen Belgium and Janssen United Kingdom.
Bruce is a respected Industry Leader and is currently an elected Director and Board Member of Medicines Australia, a role he has also held previously. Whilst in Japan he served as the Vice Chair of the Japan Based Executive Committee of the Pharmaceutical Research and Manufacturers of America (PhRMA).
Bruce has a strong track record in advocating for policies that support timely and affordable access to innovative medicines and has recently been appointed as a Director and Board member of the Australian Genomic Cancer Medicine Centre. In 2017 he was also a key member of the Cancer Drugs Access Committee.
Bruce holds an Economics degree from Macquarie University, an MBA from Macquarie Graduate School of Management, and is a Graduate Member of the Australian Institute of Company Directors (GAICD).